SRR12475116
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.410
- E2F_TARGETS+0.380
- PROTEIN_SECRETION+0.370
- MTORC1_SIGNALING+0.360
- INTERFERON_GAMMA_RESPONSE+0.340
- G2M_CHECKPOINT+0.300
- BILE_ACID_METABOLISM+0.260
- XENOBIOTIC_METABOLISM+0.250
- ANDROGEN_RESPONSE+0.220
- INFLAMMATORY_RESPONSE+0.220
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.380
- MYOGENESIS-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- APICAL_SURFACE-0.320
- TGF_BETA_SIGNALING-0.280
- APICAL_JUNCTION-0.270
- HYPOXIA-0.270
- MYC_TARGETS_V2-0.250
- UV_RESPONSE_UP-0.210
- ESTROGEN_RESPONSE_EARLY-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 90c9f8cd-4c8c-4f07-af2f-e17db69bd561 | — | — | 0.813 |
| 2 | TCGA-E9-A248-01A-11R-A169-07 | — | C | 0.757 |
| 3 | 06d5607b-45d7-4247-8d42-709d9d292530 | — | — | 0.747 |
| 4 | C3L-02654 | — | cohortA1 | 0.738 |
| 5 | 66b4502b-d393-4664-a317-430ec1ad4b3b | — | — | 0.733 |
| 6 | R355 | — | — | 0.728 |
| 7 | TCGA-BH-A1F8-01A-11R-A13Q-07 | — | B | 0.726 |
| 8 | GSM6454730 | — | D | 0.716 |
| 9 | 82924 | EPN | Supratentorial EPN | 0.715 |
| 10 | 004589d9-7eb6-46cb-b822-20cd1939aa7e | — | — | 0.715 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |